Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Apr 17;21(2):240228.
doi: 10.1183/20734735.0228-2024. eCollection 2025 Apr.

A case of pulmonary and cutaneous sarcoidosis

Eimear Foley  1 , Ahmad Basirat  1 , Ankit Yadav  1 , Shane O'Brien  1   2 , Patrick D Mitchell  1   2 , Seamas C Donnelly  1   2
Affiliations
Case Reports

A case of pulmonary and cutaneous sarcoidosis

Eimear Foley et al. Breathe (Sheff). .

Abstract

A case demonstrating refractory cutaneous and pulmonary sarcoidosis, with classic clinical, spirometry and radiological features, despite OCS and low-dose HCQ treatment that responded clinically and functionally to the addition of a TNF inhibitor https://bit.ly/4h8Gix1.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors have nothing to disclose.

Figures

FIGURE 1
FIGURE 1
a) Photograph showing indolent reddish-purple plaques and nodules on the patient's nose, cheeks and eyelids with associated telangiectasia. b) Close-up image of the right nasal rim.
FIGURE 2
FIGURE 2
Photograph of the patient's facial lesions.
FIGURE 3
FIGURE 3
a) Chest radiograph. b) High-resolution computed tomography of the thorax.
FIGURE 4
FIGURE 4
a) Endobronchial image captured at bronchoscopy demonstrating inflamed erythematous airways. b) Endobronchial image captured at bronchoscopy demonstrating airway nodularity.
FIGURE 5
FIGURE 5
Follow-up 4 months after starting tumour necrosis factor-α antagonist treatment.
FIGURE 6
FIGURE 6
Follow-up imaging 9 months after starting tumour necrosis factor-α antagonist treatment.
See this image and copyright information in PMC

References

    1. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003; 361: 1111–1118. doi: 10.1016/s0140-6736(03)12888-7 - DOI - PubMed
    1. Mitchell DN, Scadding JG, Heard BE, et al. Sarcoidosis: histopathological definition and clinical diagnosis. J Clin Pathol 1977; 30: 395–408. doi: 10.1136/jcp.30.5.395 - DOI - PMC - PubMed
    1. Ungprasert P, Carmona EM, Utz JP, et al. Epidemiology of sarcoidosis 1946–2013: a population-based study. Mayo Clin Proc 2016; 91: 183–188. doi: 10.1016/j.mayocp.2015.10.024 - DOI - PMC - PubMed
    1. Polychronopoulos VS, Prakash UBS. Airway involvement in sarcoidosis. Chest 2009; 136: 1371–1380. doi: 10.1378/chest.08-2569 - DOI - PubMed
    1. Dhooria S, Sehgal IS, Agarwal R, et al. High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial). Eur Respir J 2023; 62: 2300198. doi: 10.1183/13993003.00198-2023 - DOI - PubMed

Publication types

LinkOut - more resources